HOUSTON--(BUSINESS WIRE)--May 8, 2015--
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage
biopharmaceutical company focused on discovering and developing novel
cellular immunotherapies, today announced that it has entered into a
lease agreement to enable in-house cell therapy manufacturing to supply
clinical trials. The additional 27,000 square feet will be located in
the Company’s current headquarters building adjacent to the Texas
Medical Center in Houston.
“Bringing manufacturing in-house allows us to build upon our process and
assay development expertise and streamline the production of our cell
therapy product candidates, under our full control,” said Tom Farrell,
Bellicum’s President and Chief Executive Officer. “The planned facility
is intended to provide study drug for clinical studies of BPX-501 and to
support the development of our expanding pipeline of TCR and CAR-T
adoptive cell therapy product candidates.”
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing novel cellular immunotherapies for various
forms of cancer, including hematological cancers and solid tumors, as
well as orphan inherited blood disorders. The Company is using its
proprietary Chemical Induction of Dimerization, or CID, technology
platform to engineer and control components of the immune system in real
time. Bellicum is developing next-generation product candidates in some
of the most important areas of cellular immunotherapy, including
hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy,
and dendritic cell vaccines.
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
timing of our clinical trials and of our research and development
activities relating to BPX-501 and our expectations regarding our other
programs. Various factors may cause differences between Bellicum’s
expectations and actual results as discussed in greater detail in
Bellicum’s filings with the Securities and Exchange Commission,
including without limitation our annual report on Form 10-K for the year
ended December 31, 2014. Any forward-looking statements that Bellicum
makes in this press release speak only as of the date of this press
release. Bellicum assumes no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Source: Bellicum Pharmaceuticals, Inc.
Brad Miles, 646-513-3125